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Luc J. W. van der Laan  2, Rudi W. Hendriks3 & Carla C. Baan1
tissue-resident memory t (tRM) cells are characterized by their surface expression of CD69 and can be 
subdivided in CD103+ and CD103− tRM cells. The origin and functional characteristics of TRM cells in 
the renal allograft are largely unknown. To determine these features we studied TRM cells in transplant 
nephrectomies. TRM cells with a CD103+ and CD103− phenotype were present in all samples (n = 13) 
and were mainly CD8+ T cells. Of note, donor-derived TRM cells were only detectable in renal allografts 
that failed in the first month after transplantation. Grafts, which failed later, mainly contained recipient 
derived tRM cells. The gene expression profiles of the recipient derived CD8+ tRM cells were studied in 
more detail and showed a previously described signature of tissue residence within both CD103+ and 
CD103− tRM cells. All CD8+ tRM cells had strong effector abilities through the production of IFNγ and 
TNFα, and harboured high levels of intracellular granzyme B and low levels of perforin. In conclusion, 
our results demonstrate that donor and recipient tRM cells reside in the rejected renal allograft. Over 
time, the donor-derived TRM cells are replaced by recipient tRM cells which have features that enables 
these cells to aggressively respond to the allograft.
Over the last two decades, the presence and importance of a non-migrating subset of memory T cells survey-
ing immune responses in non-lymphoid tissues has been recognized: the so-called tissue-resident memory T 
(TRM) cells1,2. Their restricted anatomical localization in combination with their effector memory phenotype ena-
bles TRM cells to rapidly respond to local antigens. Today, two distinct subsets of TRM cells have been identified: 
CD69+CD103+ and CD69+CD103− TRM cells (hereafter referred to as CD103+ TRM cells and CD103− TRM 
cells, respectively)3–6. CD69 is a C-type lectin that was originally identified as a marker of activated T cells but 
is also involved in tissue retention of TRM cells2,7–9. CD69 binds to and down-regulates the G protein-coupled 
receptor sphingosine 1 phosphate (S1PR1) expressed on the T cell membrane, resulting in a decreased ability of 
TRM cells to sense the S1P gradient that promotes migration of memory T cells from the blood into peripheral 
tissue7–9. A unique TRM cell gene expression profile has recently been identified by Kumar et al. with 31 core genes 
that are differentially up- or downregulated in CD69+ TRM cells isolated from human lung and spleen10. The other 
recognized TRM marker, CD103, is an αE integrin that binds E-cadherin which is expressed on epithelial tissues11. 
Today, no clear consensus exists about the functional differences between CD103+ and CD103− TRM cells.
Although the presence and antigen specificity of TRM cells is recognized in several non-lymphoid human 
tissues (e.g. skin, liver, lungs, intestine and brain), the presence and function of TRM cells in the human kidney 
is currently unknown4,5,12–16. In experimental mouse models, it was demonstrated that TRM cells homed to the 
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kidney where they resided, and that this migration was promoted by TGF-β17,18. Otherwise, little is known about 
the functional properties of these kidney TRM cells19.
Transplantation of a renal allograft is accompanied by the transfer of donor leucocytes. It is probable that these 
leucocytes also include donor-derived TRM cells. It is, however, unknown if these cells persist after transplantation 
or whether they are replaced by TRM cells of recipient origin. It is therefore informative to identify the donor or 
acceptor origin of these cells and thus the degree of chimerism. This will help us to understand if donor TRM cells 
are present in the allograft to control local viral and bacterial responses20 and whether these TRM cells might be 
enriched for graft-versus-host (GvH) reactive clones, as seen in intestinal transplant patients21–23. The presence of 
recipient TRM cells will shed light on their potential role in alloreactivity and will show if recipient T cells differ-
entiate into TRM cells in the renal allograft.
Here, we postulate that TRM cells are present in the renal allograft and that these cells are primarily from recip-
ient origin and are capable of mounting an allo-reactive response. To this end, we used the unique tissue resource 
of transplant nephrectomies from immunosuppressed patients to study the presence, provenance (donor or recip-
ient), and the effector phenotype of CD103+ TRM cells (CD69+CD103+), CD103− TRM cells (CD69+CD103−), 
and recirculating T cells not expressing the tissue retention markers CD69 and CD103 (CD69−CD103−). We 
performed similar control experiments with spleen cells of organ donors, a lymphoid cell population in which 
TRM cells are known to be present3,10.
Results
T cells of donor and recipient origin are present in the renal allograft. Thirteen transplant nephrec-
tomy specimens were studied. Patient demographics are listed in Table 1. These kidney allografts failed either 
acute (n = 4) or chronically (n = 9) as a result of humoral, cellular or mixed-type rejection and were removed after 
a mean time of 6.1 years (range: 8 days–26 years).
After the isolation procedure, CD3+ T cells were detected in all renal allografts with a median propor-
tion among the total viable lymphocytes of 72.1% (range: 30.1–78.5%; Fig. 1A). Of the CD3+ T cells, 37.6% 
Recipient Transplantation
Gender
Age at 
nephrectomy (y) Cause of ESRD
Number of 
previous 
renal 
transplants Donor type
CMV status 
donor*
CMV status 
acceptor*
Maintenance 
IS
Anti-rejection 
treatment
Time to 
explantation 
(days)
Cause of graft 
failure
1. M 30 Hypertensive nephropathy 0 L − +
Tac, MMF, 
Pred
MP, IvIg, 
plasmaferese, 
Alemtuzumab
8
aTCMR2B and 
aABMR and 
pyelonephritis
2. F 48 ADPKD 0 L − +
Bela, Tac**, 
MMF, Pred, 
Basiliximab
MP, 
Alemtuzumab 12
aTCMR2B and 
aABMR
3. M 63 Hypertension nephropathy 0 D + +
Tac, MMF, 
Pred, 
Basiliximab
MP, IVIg 15 aTCMR 2B and aABMR
4. F 28 GPA 1 L + − Tac, MMF, Pred
IVIg, 
Alemtuzumab 150
aTCMR3 and 
aABMR
5. M 46 ADPKD 0 L + − Tac, MMF, Pred MP 270 aTCMR3
6. F 67 Hypertension nephropathy 0 D − + None
# MP 390 aTCMR3 and aABMR
7. M 71 Diabetic nephropathy 1 D + + Tac, MMF MP 2268
aTCMR3 and
c-aABMR
8. M 29 HUS 0 D − − Tac, MMF None 2340 c-aABMR
9. M 24 FSGS 0 L + + MMF, Pred, Ecu*** MP, IVIg 2520 c-aABMR
10. M 51 Congenital hydronephrosis 0 D − − Tac None 3240
aTCMR2B and 
aABMR
11. F 51
poststreptococcal 
glomerulo- 
nephritis
0 D + − None# None 3780 c-aABMR andc-aTCMR
12. M 53 Hypertension nephropathy 1 L + + Tac, Pred None 4320 aTCMR3
13. M 57 Hypertension nephropathy 0 D + + Aza, Pred None 9360
End-stage 
kidney
Table 1. Patient baseline characteristics. *CMV status prior to transplantation. **Switch from Belatacept 
to Tacrolimus due to rejection. ***No tacrolimus due to thrombotic microangiopathy. #Decreased IS and 
restarted dialysis. aABMR = acute antibody mediated rejection; ADPKD = autosomal dominant polycystic 
kidney disease; aTCMR = acute T cell-mediated rejection; Aza = azathioprine; CMV = cytomegalovirus; 
D = deceased; Ecu = eculizumab; ESRD = end-stage renal disease; FSGS = focal segmental glomerulosclerosis; 
GPA = granulomatosis with polyangitis; HUS = hemolytic uremic syndrome; IS = immunosuppression; 
IVIg = intravenous immunoglobulin; L = living; MP = methylprednisolone; MMF = mycophenolate mofetil; 
Pred = prednisone; Tac = tacrolimus.
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(22.9–83.2%) were CD8+ and 47.4% (13.1–70.0%) were CD4+ T cells (Fig. 1A). The CD3+ T cells isolated 
from nephrectomy number three and four (Table 1) were capable of mounting an allogeneic response, since both 
the proportions of proliferating cells and the expression of the degranulation marker CD107a increased in the 
presence of donor antigen, while a negligible response was measured after stimulation with irradiated recipient 
PBMCs (Supp. Fig. 1A,B). In addition, the cells of patient number three reacted to a fully HLA mismatched 3rd 
party and responded to donor antigen by the production of IFNγ (Supp. Fig. 1A–C).
Next, the degree of chimerism was studied in the explanted renal allografts. Conjugated HLA-mAbs were 
available to distinguish recipient from donor cells in ten renal lymphocyte samples. In the example depicted in 
Fig. 1B (upper panel), the proportions of donor cells measured by a mAb against HLA-B7 (donor positive) and a 
mAb against HLA-B70 (acceptor positive) resulted in similar donor proportions of 1.71% and 1.70% respectively, 
showing chimerism in this sample. Three out of the ten renal allografts studied were removed within the first 
month after transplantation (Table 1). In these renal allografts, clear populations of CD4+ and CD8+ T cells from 
donor origin were detected (Fig. 1C). The renal allografts removed five months or later after transplantation only 
contained marginal proportions (<0.5%) of donor-derived T cells, and we could not distinguish a clear positive 
and negative fraction in these samples as depicted in the dot plots of patient number 7 in Fig. 1B (lower panel). 
Thus, high proportions of donor-derived T cells were only seen in early rejection nephrectomies.
tRM cells are present in the renal allograft. The absence of TRM cells in PBMC fractions and the pres-
ence of TRM cells in the spleen was recognized in previous studies3,10. Subsequently we used PBMCs from healthy 
controls as a negative control and splenocytes of deceased organ donors as a positive control for TRM cell iden-
tification. CD69+ TRM cells were present in all transplant nephrectomy specimens with a median proportion of 
Figure 1. CD8+ and CD4+ T cells of donor and recipient origin are present in the renal allograft. 
Lymphocytes were isolated from the rejected renal allografts and subsequently stained and analysed by flow 
cytometry. (A) Gating strategy used to detect CD3+ T cells within the total viable lymphocytes, of which the 
CD8+ and CD4+ T cells were selected. (B) Typical examples of renal lymphocyte samples of patient number 
three and seven stained with mAb against human leukocyte antigen (HLA) class I antigens within the CD4+ 
T cells. Proportions of cells originating from the donor are depicted. (C) Table with numbers referring to 
the renal allografts described in Table 1, the time to explantation in days, and the proportions of donor cells 
detected within the CD8+ and CD4+ T cell compartment. Frequencies of the cells are presented as individual 
proportions with medians. HLA = human leukocyte antigen; N.S. = not significant; N/D = not determined.
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Figure 2. TRM cells are present within CD8+ and CD4+ T cells in the renal allograft. Lymphocytes from 
rejected renal allografts, spleens of organ donors, and blood from healthy individuals were stained with 
mAb against CD69 and CD103. (A) Representative examples of the gating strategy of CD69 and CD103 of 
lymphocytes originating from the renal allograft, spleen, and blood. Proportions of the gated areas are depicted 
within the dot-plots. (B,C) Quantified data of the recirculating T cells (CD69−CD103−), CD103− TRM cells 
(CD69+CD103−), and CD103+ TRM cells (CD69+CD103+) subsets within the CD8+ T cell compartment 
(B) and CD4+ T cell compartment (C) of the renal allograft, spleen, and blood (blood n = 5, spleen n = 10, 
renal allograft n = 13). Frequencies of the cells are presented as individual proportions with medians. Significant 
differences were calculated and presented (*p < 0.05, **p < 0.01, ***p < 0.001). (D) mAb against HLA class 
I antigens were used to discriminate between donor and recipient lymphocytes. Typical example dot plots 
and quantified data of proportions of donor-derived cells within the CD103+ TRM cells, CD103− TRM cells 
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73.2% in the CD8+ T cell compartment and 62% in the CD4+ T cell compartment (Fig. 2A). We subdivided 
the TRM cells in CD103+ TRM (CD69+CD103+) cells and CD103− TRM cells (CD69+CD103−). The median 
proportion of CD103+ TRM cells within the CD8+ T cell compartment was 32.3% (range: 4.5–54.4%) compared 
to 1.4% (0.7–8.8%) within the CD4+ T cell compartment. In contrast, CD103− TRM cells were more evenly dis-
tributed among the CD8+ (40.9%, 9.4–78.8%) and CD4+ (60.6%, 20.2–81.2%) T cell compartments (Fig. 2B,C). 
As expected, minimal proportions of CD103+ TRM cells and CD103− TRM cells were found in peripheral blood, 
while both TRM cell subsets were present in the spleen (Fig. 2). Similar proportions of CD4+ and CD8+ TRM 
cells were detected in two native kidneys that were discarded for transplantation (Supp. Fig. 2). No significant 
differences were detected when we subdivided the CD103+ and CD103− TRM cells of the transplant nephrec-
tomies based on donor type, Banff 2017 category and time to explantation (Supp. Fig. 3A–C). Of interest might 
be the observation that in chronic-active antibody-mediated rejection (c-aABMR) specimens the proportion of 
CD103− TRM cells was low (Supp. Fig. 3B). However, this observation is only based on two c-aABMR cases.
We questioned whether TRM cells of donor or recipient origin were present in the kidneys explanted in the first 
month after transplantation (Fig. 1C). For that we stained the renal lymphocytes of the transplant nephrectomies 
removed within the first month after transplantation (patients 1–3, Table 1) again with antibodies recognizing 
either donor or recipient HLA molecules. Remarkably, donor-derived lymphocytes were most prominent within 
the CD103+ TRM cell population, with lower levels of donor cells in the CD103− TRM cells and recirculating T 
cell compartments (Fig. 2D). This was observed for both CD8+ and CD4+ donor T cells. These data suggest the 
increased ability of donor-derived CD103+ TRM cells to reside in the renal allograft compared to the remaining 
donor-derived T cells.
Because the proportion of CD103+ TRM cells was very low among the CD4+ T cells, not allowing further 
analysis, we focused on the CD8+ TRM cells for subsequent experiments. In addition, the three renal allografts 
explanted within the first month after transplantation were excluded in order to study a pure population of recip-
ient TRM cells that may mediate and control the local immune response.
expression of tRM signature genes. To define the gene expression profile of the TRM cells, we selected 8 
genes from a set of signature genes described by Kumar et al. that are differentially expressed between CD69− 
and CD69+CD8+ T cells isolated from the spleen and lung10. We compared the expression of these genes in 
cells isolated form the renal allograft and in splenocytes in the following FACS-sorted CD8+ T cell populations: 
CD69+CD103+ TRM cells, CD69+CD103− TRM cells, and CD69−CD103− (recirculating) T cells. The gating 
strategy for the FACS sort experiments is depicted in Fig. 3A.
We used RT-qPCR to quantify the expression of genes that are involved in pathways that mainly control T cell 
migration, adhesion and activation. Separate heat maps were created of the gene expression levels of the renal 
allograft and spleen (Fig. 3B). Overall, two clusters were identified in the heat maps of both the renal allograft 
and spleen: a cluster of genes upregulated in the total TRM cells (CD103+ and CD103− TRM cells) and a cluster of 
genes downregulated in the total TRM cells, compared to the recirculating T cells (Fig. 3B). The gene expression 
levels of the adhesion marker ITGA1 (CD49a) were especially high in the CD103+ TRM cells, with lower expres-
sion levels in the CD103− TRM cells and recirculating T cells. Chemokine receptor CXCR6 and cytokine IL-10 
were clearly expressed at a higher level in the total TRM cell subsets compared to the recirculating T cells. In both 
the spleen and renal allograft samples, the T cell trafficking and homing markers S1PR1, Kruppel-like transcrip-
tion factor 2 (KLF2), SELL (CD62L), KLF3 and CX3CR1 were expressed at a lower level in the total TRM cells 
compared to the expression levels in the recirculating T cells. When we clustered the FACS-sorted samples of the 
renal allograft and spleen, the CD103+ TRM cells and CD103− TRM cells clearly clustered together as opposed to 
the recirculating T cells (Supp. Fig. 4). In summary, the total population of TRM cells can be clearly distinguished 
from the recirculating T cells based on their gene expression profile. In addition, similar gene expression levels 
were found in the different T cell subsets when comparing the renal allograft and the spleen samples.
tRM cells in the renal allograft have an effector memory phenotype. To demonstrate that 
the CD8+ TRM cells found in the renal allograft have an effector phenotype we stained the cells for the sur-
face molecules CCR7 and CD45RO. With these markers naïve (CCR7+CD45RO−), central memory (CM, 
CCR7+CD45RO+), effector memory (EM, CCR7−CD45RO+) and highly-differentiated effector memory 
(EMRA, CCR7−CD45RO−) T cells were discriminated (see Fig. 4A for a typical example). While the recirculat-
ing T cells in the renal allograft and spleen were more divergent in terms of CCR7 and CD45RO expression, the 
majority of the CD103− TRM cells and CD103+ TRM cells were CCR7−CD45RO+ and thus EM T cells (Fig. 4B). 
This finding is in line with previous studies in non-lymphoid tissues where the majority of TRM cells was also of 
an EM phenotype3,10.
tRM cells are capable of producing effector molecules. The capacity of the cells to produce the 
pro-inflammatory cytokines IFNγ and TNFα was measured after polyclonal stimulation. No change in the 
expression and proportion of CD69+ cells before and after three hours of polyclonal T cell stimulation was 
observed, in contrast to an altered expression of CD69 and CD103 on the CD8+ T cells after seven days allostim-
ulation (Supp. Figs 5 and 6). Subsequently, we compared the TRM cell subsets and the recirculating T cells after 
stimulation for their cytokine production capacity.
and recirculating T cells are depicted of the transplant nephrectomies removed within the first month after 
transplantation (Table 1, patient 1 to 3). Frequencies of the positive cells are depicted within the dot plots. 
Frequencies of positive cells are shown as mean with the SEM (n = 3; N.S. = not significant).
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After stimulation, all resident and recirculating CD8+ T cell subsets expressed high levels of IFNγ (Fig. 5A). 
A slightly higher expression in the IFNγ production capacity was observed in the CD103+ TRM cells in both renal 
allograft and spleen compared to the recirculating and CD103− TRM cell subsets (Fig. 5A). For TNFα, a different 
profile was found with the highest expression levels in the recirculating T cells, lower levels in the CD103− TRM 
cells and the lowest levels in the CD103+ TRM cells (Fig. 5B). Within the spleen, the differences in TNFα propor-
tions were significantly different between the different subsets (Fig. 5B). Highly effector CD8+ T cells that were 
concurrently positive for IFNγ and TNFα were present in both the renal CD103− and CD103+ TRM cells (Supp. 
Fig. 7).
To determine the degranulation capacity of the different CD8+ TRM cell subsets, intracellular granzyme B 
and perforin expression were measured (Fig. 5C,D). In the renal allograft, the intracellular granzyme B levels did 
not significantly differ between the recirculating T cells, the CD103− TRM cells and CD103+ TRM cells (Fig. 5C). 
The granzyme B levels within the spleen were significantly lower in the CD103+ TRM cells compared to both 
the recirculating T cells and the CD103− TRM cells. With regard to the intracellular levels of perforin, the same 
trend between the different subsets was found in the renal allograft samples compared to the spleen samples 
(Fig. 5D). The perforin levels were significantly lower in the CD103+ TRM cells compared to the recirculating T 
cells (Fig. 5D). Together, these data show that TRM cells, but also the recirculating T cells, are capable of mounting 
and effector response.
Discussion
In this study, we demonstrate that (1) T cells with a resident memory phenotype and gene expression profile are 
present in the renal allograft, (2) TRM cells in the renal allograft have strong immunostimulatory capacity, and (3) 
the donor-derived cells present are mainly CD103+ TRM cells and are replaced by recipient-derived T cells within 
five months after transplantation. An overview of these findings is depicted in Fig. 6.
No major differences were found in gene expression signature and functional profiles between the CD103+ 
TRM and CD103− TRM cells, highlighting that these two TRM cell subtypes have comparable characteristics. 
Figure 3. Expression of TRM signature genes. (A) Typical example of the gating strategy used after 
fluorescence activated CD8+ cell sorting to obtain recirculating T cells (CD69−CD103−), CD103− TRM cells 
(CD69+CD103−), and CD103+ TRM cells (CD69+CD103+). Cells were gated by forward- and side-scatter 
followed by 7-AAD negative (viable) gating. (B) Heatmaps depicting the normalized gene expression of eight 
signature genes known to be upregulated (yellow) or downregulated (blue) in TRM cells of the renal allograft and 
spleen. Spleen n = 5, renal lymphocytes n = 4.
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Previous studies report that CD103+ TRM cells reside more predominantly within the barrier tissues while 
CD103− TRM cells are more common within non-barrier tissues18. In transplantation, CD8+CD69−CD103+ 
T cells are involved in the effector mechanism of chronic and acute renal allograft rejection24–27. In addition, in 
urinary samples, the mRNA levels of CD103 predicted acute renal allograft rejection28. However, in the context 
of kidney transplantation the exact difference in CD103+ and CD103− TRM cells is unknown and of interest for 
further analysis.
The majority of the TRM cells detected in the renal allograft were of an effector memory phenotype. Therefore, 
these cells have been antigen challenged and are able to rapidly exert immunological responses. Both the CD103+ 
and CD103− TRM cell subsets had the capacity to produce TNFα, a cytokine involved in, among others, the acti-
vation of endothelial cells, thereby attracting other T cells to the site of inflammation29. The capacity of the TRM 
cells to produce IFNγ and the presence of preloaded granzyme B positive granules underlines their cytotoxic phe-
notype. Low levels of perforin were measured in the TRM cells which is in line with previous studies30,31. In these 
studies, perforin was rapidly upregulated upon antigen stimulation, delineating a dynamic process30,32. Here we 
found that TRM cells present in renal allografts are potentially harmful cells that might contribute to the process 
of allograft rejection. However, additional experiments need to clarify the exact roles of the TRM cell subsets in 
the alloimmune response and show causality. For future studies, it would be of interest to include the number of 
cells per gram tissue. The functional profiles of the TRM subtypes found in the renal allograft were comparable to 
those found in the TRM subsets residing in the spleen. This supports that we have identified TRM cells in the renal 
allograft.
Memory T cell signalling is still occurring under immunosuppression because these cells are less reliant on 
co-stimulatory signals33–36. For this reason, we can hypothesize about the long lasting persistence of TRM cells 
within the renal allograft. Also, the distribution of immunosuppressive agents into the tissue may influence the 
presence of TRM cells. For instance, alemtuzumab depletes circulating CM T cells in leukemic cutaneous T cell 
lymphoma patients without completely compromising the immune response to infection, since the skin resident 
memory cells are spared37. The samples analysed in this study are a heterogeneous group with different types of 
end-stage immunological transplant failure. Further study on the differentiation and function of TRM cells upon 
Figure 4. TRM cells in the renal allograft have an effector memory phenotype. (A) Typical examples of 
dot plots presenting the distribution of naïve T cells (CCR7+CD45RO−), central memory T cells (CM; 
CCR7+CD45RO+), effector memory T cells (EM; CCR7−CD45RO+), and EMRA T cells (CCR7−
CD45RO−) within the CD8+ recirculating T cells, CD103− TRM cells and CD103+ TRM cells of the renal 
allograft. Numbers within the dot plots indicate proportions of the different cell subsets. (B) Pie charts 
representing the median proportion of naïve, central memory, effector memory, and EMRA T cells within the 
CD8+ recirculating T cells, CD103− TRM cells and CD103+ TRM cells of the renal allograft and spleen (renal 
lymphocytes n = 6, spleen n = 8).
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transplantation, would benefit from similar studies on cells harvested from healthy renal tissue or grafts undergo-
ing an evolving rejection, which for obvious reasons is not possible in transplant recipients. The best alternative 
for healthy renal tissue would be the use of kidneys discarded for transplantation. Our first findings showed the 
presence of TRM cells in these kidneys with comparable frequencies of CD103− and CD103+ TRM cells as found 
in the transplant nephrectomies.
The results of our study reveal that donor-derived lymphocytes are replaced by their recipient counterparts 
within five months after transplantation and that the recipient-derived T cells differentiate locally towards a res-
ident memory phenotype. The rapid presence of recipient TRM cells in these specimens sheds light on the impor-
tant role of this cell type in the process of alloreactivity. The repopulation by recipient lymphocytes has also 
been observed in lung and intestinal allografts38,39. The prolonged retention of the CD103+ TRM cells compared 
to the other donor-derived T cells supports that this subtype of TRM cells is highly capable to bind to epithe-
lial cells of the renal allograft (Fig. 6). The retention of donor-derived TRM cells might have a protective role in 
the renal allograft since irradiation of donor cells in rodent models resulted in rejection of liver transplants40,41. 
Also, in visceral transplant patients, T cell chimerism is observed in the absence of graft-versus-host disease 
Figure 5. TRM cells are capable of producing effector molecules. (A,B) Proportions of IFNγ (A) and TNFα 
(B) producing cells are depicted upon 4 hours PMA/ionomycin stimulation in the presence of monensin and 
brefeldin A. Cytokine proportions were measured in renal lymphocytes and splenocytes within the recirculating 
T cells, CD103− TRM cells, and CD103+ TRM cells of the CD8+ T cell compartment. (C,D) Frequencies of 
granzyme B (C) and perforin (D) levels were measured in the recirculating T cells, CD103− TRM, and CD103+ 
TRM cells of the CD8+ T cell compartment. Frequencies of positive cells were shown as mean with the SEM 
(renal lymphocytes n = 6, spleen n = 10). Significant differences were calculated and depicted (N.S. = not 
significant, *p < 0.05, **p < 0.01).
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(GVHD)21. Donor-derived cells with graft specific TCR clones are even thought to slow down the constant threat 
of recipient-derived T cells, illustrating that the balance between graft-versus-host (GvH) and host-versus-graft 
(HvG) clones in situ influences lymphocyte turnover and development of rejection22. A rapid clearance of the 
donor-derived cells may thus contribute to the rejection of the renal allograft. The low IFNγ-producing response 
of the renal lymphocytes to recipient PBMCs that we measured might be due to the mixed population of donor 
and recipient cells within the renal lymphocytes. This observation might be a reflection of the potential GvH 
response which may also explain a lower response to the donor cells, in line with the findings of Zuber et al.22. 
For future experiments, it is of interest to compare the GvH and HvG T cell balance in protocol biopsies at differ-
ent time points after transplantation and compare this balance between patients with and without rejection. In 
addition to the response to the allograft, TRM cells also recognize and clear pathogens. Therefore, it is tempting to 
speculate that the TRM cells are both friends and foes to the renal allograft. Virus-specific TRM cells are known to 
be able to quickly exert their effector function within the peripheral tissue, and thus the TRM cells present in the 
renal allograft may also exert this function20,42. Therefore, the precise contribution of donor and recipient TRM 
cells to alloreactivity is of high interest for future studies.
In conclusion, our results demonstrate that TRM cells are present in the human renal allograft and that 
donor-derived TRM cells are replaced within the first months after transplantation by recipient TRM cells, which 
have the capacity to aggressively respond to the allograft. Understanding the potentially destructive or protective 
roles of the TRM cells in the renal allograft is of high interest to enhance renal transplant outcomes.
Materials and Methods
Study population. Thirteen transplant nephrectomy specimens and two kidneys that were discarded for 
transplantation were studied. The characteristics of the patients from whom the transplant nephrectomies were 
derived are described in Table 1. Of these nephrectomies, the pathological features corresponding to the type 
of renal allograft rejection were classified according to the Banff ’17 classification43. In this study, residual mate-
rial previously used for histopathological diagnosis was analysed. Residual materials were used in accordance 
with non-WMO compliant research that is regulated by the Dutch Code of Conduct (Federa). Splenocytes were 
obtained from deceased organ donors and peripheral blood mononuclear cells (PBMCs) were from healthy 
controls. The Medical Ethical Committee of the Erasmus MC, University Medical Center, approved this work 
(MEC-2010-022). All experiments were performed in accordance with relevant guidelines and regulations as 
described by our institution. All patients gave written informed consent. No organs were procured from (exe-
cuted) prisoners.
Isolation of lymphocytes. Half of the renal allograft (cortex and medulla) was processed towards a single 
cell suspension, the other half was used for routine diagnostic assessment. The renal allograft was thoroughly 
rinsed with PBS to remove peripheral cells and afterwards dissected into small pieces (<0.5 cm3) and incubated 
for 60 minutes at 37 °C with 1.1 mg/ml collagenase IV (Serva, Heidelberg, Germany). The collagenase treatment 
was stopped by the addition of heat-inactivated fetal bovine serum with an end concentration of 10%. The tissue 
suspension was filtered through different sieves up to a 100 μm sieve (Greiner Bio-One, Kremsmünster, Austria) 
followed by a Ficoll-Paque Plus procedure (GE healthcare, Uppsala, Sweden). Isolated cells were stored at −190 °C 
Figure 6. Schematic overview of TRM cell characteristics in the renal allograft. Distribution of donor-derived 
and recipient-derived tissue-resident memory (TRM) cells and the phenotypic and functional characteristics of 
the recipient-derived TRM cells in the explanted renal allograft are depicted in a schematic overview. Cluster one 
and cluster two indicate TRM core genes of which the expression was measured. Cluster one consists of genes 
involved in T cell activation (ITGA1, IL10, and CXCR6) and cluster two consists of genes involved in T cell 
migration (CX3CR1, KLF2, KLF3, SELL, S1PR1).
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until further use. Afterwards, cells were thawed and analysed by flow cytometry and reverse transcription-qPCR 
(RT-qPCR) to determine their phenotype and gene expression profile.
Human splenocytes were disrupted and filtered through a 70 μm cell strainer (Greiner Bio-one, Alphen 
a/d Rijn, The Netherlands) to obtain a single-cell suspension. Ficoll-paque (Amersham Pharmacia Biotech, 
Uppsala, Sweden) density gradient was used to collect mononuclear cells. Human PBMCs were isolated with the 
Ficoll-paque density gradient method.
Flow cytometric and functional analysis. Renal lymphocytes, splenocytes and PBMCs were stained 
with the following antibodies to characterize the TRM phenotype: CD3 brilliant violet 510 (BV510; Biolegend, San 
Diego, CA, USA), CD8 Allophycocyanin-Cy7 (APC-Cy7; Biolegend), CD4 fluorescein isothiocyanate (FITC; 
BD, Franklin Lakes, New Jersey, USA) CD69 brilliant violet 421 (BV421; BD), CD103 phycoerythrin-cyanine7 
(PE-Cy7; Biolegend). Viability was measured with the live-dead marker 7-aminoactinomycin (7-AAD; BD). FACS 
flow enriched with bovine serum albumin was used to wash the cells and block a-specific antibody interactions.
The donor or acceptor origin of the cells was determined with monoclonal antibodies (mAb) directed against 
human leukocyte antigen (HLA) class I antigens of the donor or acceptor. mAb used are listed in Supplemental 
Table 1, and were developed at Leiden University Medical Centre. We performed single labelling with either an 
antigen for which solely the donor was positive or solely the acceptor was positive.
The cytotoxic potential of TRM cells was analysed by measuring intracellular granzyme B and perforin. Cells 
were stained as described above for TRM cells. Afterwards, the cells were immediately fixed with FACS lysing solu-
tion (BD) and permeabilized with PERM II (BD). Subsequently, cells were stained intracellularly with granzyme 
B Allophycocyanin (APC) (Biolegend) and perforin phycoerythrin (PE; Biolegend).
The cytokine-producing capacity of the cells was measured after the cells were stimulated for four hours 
with 50 ng/ml phorbol myristate acetate (PMA) and 1 μg/ml ionomycin (Sigma-Aldrich, St. Louis, MO, USA) 
at 37 °C. Monensin and Brefeldin A (GolgiStop and GolgiPlug, BD Biosciences, Franklin Lakes, NJ, USA) were 
used to promote intracellular accumulation of the cytokines. PMA/ionomycin stimulation was stopped by adding 
Ethylene-diamine-tetra-acetic acid. Subsequently, cells were stained with the TRM surface staining mixture and fixed 
and permeabilized as described above. The following mAb were used to measure cytokine production: interferon-γ 
(IFNγ) FITC (BD Biosciences), and tumour necrosis factor-α (TNFα) PE (Biolegend). Cell samples were measured 
on the FACSCanto II (BD) and analysed with Kaluza Analysis 1.5a software (Beckman Coulter, Brea, CA, USA).
Allogeneic reactivity. Mixed lymphocyte reactions (MLR) were performed in order to study T 
cell-reactivity of the renal lymphocytes following stimulation with donor cells, 3rd party cells, or recipient PBMCs. 
Renal lymphocytes were thawed and labelled with carboxyfluorescein succinimidyl ester (CFSE; Molecular 
Probes®, Leiden, The Netherlands). Next, the renal lymphocytes were stimulated at 5 × 104 cells per well with 
irradiated donor cells, 3rd party cells, or recipient PBMCs (40 Gray) from which the CD3+ T cells had been 
depleted with magnetic-activated cell sorting (MACS). The cells were cultured at a ratio 1:1 in human culture 
medium (HCM) and after 7 days the CFSE dilution was measured on the FACSCanto II, indicating the amount of 
proliferation. Degranulation was measured by APC-labelled anti-CD107a (BD).
IFNγ ELISPOT. The frequencies of IFNγ producing cells upon stimulation with donor cells, 3rd party 
cells, or recipient PBMCs were measured with an Enzyme-Linked ImmunoSpot (ELISPOT) assay (U-CyTech 
Biosciences, Utrecht, The Netherlands). Briefly, anti IFNγ coated plates (U-CyTech Biosciences), were seeded 
with 100,000 renal lymphocytes and 100,000 irradiated donor cells, 3rd party cells or recipient PBMCs. Upon 
overnight incubation, plates were washed and incubated with biotinylated anti-human IFNγ detection antibody 
and streptavidin-HRP conjugate followed by the addition of AEC substrate (U-CyTech Biosciences). Spots were 
analysed using the ELISPOT reader (Bioreader®-600V, BIO-SYS GmbH, Karben, Germany).
Cell sorting of TRM cells and RT-qPCR analysis. To determine the expression levels of a set of TRM key 
genes of the CD103+ and CD103− TRM cells and CD69−CD103− recirculating T cells, we performed RT-qPCR 
analysis on FACS-sorted, pure (>95%) T cell populations. Renal lymphocytes and splenocytes were sorted with the 
BD-FACSAria II SORPTM. Subsequently, cells were pelleted and snap frozen and stored at −190 °C until further use.
RNA was isolated with the RNeasy Micro Kit (Qiagen, Hilden, Germany) for the collection of high-quality 
RNA. Total RNA was subsequently reverse transcribed with oligo-dT. We used RT-qPCR to quantify the 
amount of ITGA1, IL10, CXCR6, CX3CR1, KLF2, KLF3, SELL, S1PR1, and the housekeeping gene glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH). Assay-on-demand products for the detection and quantification of 
the different genes were used and are listed in Supplemental Table 2 (ThermoFisher, Waltham, MA, USA). The 
amount of each target gene was quantified by measuring the threshold cycle (Ct), which was transformed on 
a TaqMan Real-Time PCR system to the number of cDNA copies (2(40-Ct)). The relative concentrations of the 
analysed genes were normalized to the relative concentration of the housekeeping gene GAPDH present in each 
sample. Heatmapper software was used to cluster the cell-sorted samples based on the expression of the above 
described genes44.
Statistical analysis. Statistical analyses were performed using GraphPad Prism 5 software (GraphPad 
Software; San Diego, CA, USA). Differences between paired groups were analysed with the Wilcoxon signed-rank 
test. A two-tailed p-value of < 0.05 was considered statistically significant.
Data Availability
All data generated or analysed during this study are included in this published article and the Supplementary 
Information File.
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